On February 19, 2026 Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, reported a $100 million royalty funding agreement with funds managed by RTW Investments, LP (RTW), subject to FDA approval of aglatimagene in intermediate- to high-risk, localized prostate cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This non-dilutive strategic financing will support the U.S. launch of aglatimagene besadenovec, assuming FDA approval, and will allow us to further invest in what we believe will be a world class commercial program" said Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO of Candel. "We remain on track to submit the BLA for aglatimagene in Q4 of this year, and we look forward to collaborating with the FDA to pursue an expeditious approval of aglatimagene. We are thrilled with our RTW partnership, as we seek to provide a new treatment option for patients in the early stages of prostate cancer who are treated with curative intent, a disease that has seen minimal innovation over the past two decades."

"The pivotal phase 3 clinical trial demonstrated the potential of aglatimagene besadenovec in early, localized prostate cancer, and today’s commitment reflects our confidence in Candel and the strong commercial potential of this therapy," said Roderick Wong, M.D., Managing Partner and Chief Investment Officer, RTW Investments, LP. "We are proud to partner with the Candel management team and look forward to supporting their efforts to bring this meaningful treatment to patients with localized prostate cancer."

The commercial launch royalty financing will become available upon FDA’s approval of aglatimagene, and satisfaction of certain other customary conditions. Under the terms of the agreement, RTW will receive a tiered single digit percentage of annual net sales of aglatimagene in the U.S., subject to a cap.

(Press release, Candel Therapeutics, FEB 19, 2026, View Source [SID1234662782])

On February 19, 2026 Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, reported that it will present at the BIO Investment & Growth Summit taking place in Miami Beach, Florida, March 2-3, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will highlight recent updates and progress in Azitra’s pipeline, including ATR-12, currently in a Phase 1b clinical trial in adult patients with Netherton syndrome; ATR-04, being developed in a Phase 1/2 trial for the treatment of moderate to severe EGFRi-associated dermal toxicity in adults; and ATR-01 targeting ichthyosis vulgaris, which is undergoing IND-enabling studies.

Details are as follows:

Event:

BIO Investment & Growth Summit

Date & Time:

Monday, March 2, 2026, 2:15 PM ET

Location:

Ballroom 2C, Eden Roc Miami Beach Hotel

Presenter:

Travis Whitfill, Chief Operating Officer

Registration:

View Source

During the events, members of Azitra’s management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the Company’s clinical development strategy, recent corporate achievements, and anticipated milestones.

(Press release, Azitra, FEB 19, 2026, View Source [SID1234662781])

On February 19, 2026 ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, reported that ALX Oncology leadership will participate in the Wells Fargo Executive Biotech Summit, TD Cowen 46th Annual Health Care Conference, and UBS Biotech Summit.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details of the meetings are as follows:

Wells Fargo Executive Biotech Summit

Format: One-on-one meetings
Date: February 24-25, 2026
Location: Lake Tahoe, CA

TD Cowen 46th Annual Health Care Conference

Format: Presentation
Date: March 3, 2026
Time: 9:10 AM EST
Location: Boston, MA
Webcast link: Available here

UBS Biotech Summit

Format: One-on-one meetings
Date: March 10, 2026
Location: Miami, FL

The webcast of the TD Cowen 46th Annual Health Care Conference presentation can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com under the Events section of the Events and Presentations tab. Replay of the webcast will be archived for up to 90 days following the presentation date.

(Press release, ALX Oncology, FEB 19, 2026, View Source [SID1234662779])

On February 18, 2026 Sift Biosciences, a UC Berkeley spinout developing a next-generation peptide immunotherapy platform that integrates AI, metagenomics, and high-throughput immune profiling, reported the closing of a $3.7M Pre-Seed financing, co-led by Freeflow Ventures and Lifespan Vision Ventures, with participation from Valuence Ventures, Eisai Innovation, SBI US Gateway Fund and other early supporters.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sift is building a new class of peptide-based immunotherapies designed to engage pre-existing memory T cells to overcome the lack of immunogenicity that limits current cancer immunotherapies. The company’s initial focus is on immunologically "cold" solid tumors, including microsatellite-stable colorectal and ovarian cancers, where patients have few effective treatment options.

"Most immunotherapies fail not because the immune system is weak, but because it’s never meaningfully engaged," said Clare Lou, Ph.D., CEO and Cofounder of Sift Biosciences. "By harnessing infection-trained memory T cells, we’re developing a platform that can rapidly amplify immune responses in cancers that don’t respond to today’s treatments. This financing enables us to demonstrate in vivo proof-of-concept and advance our lead programs."

Sift’s platform identifies microbial analogs of tumor-associated epitopes, enabling rapid activation of highly responsive memory T-cell populations without requiring de novo immune priming. Early preclinical studies support the potential for faster, more potent, and more durable immune responses than existing approaches.

"Sift is tackling one of the most fundamental challenges in immuno-oncology with a differentiated and biologically grounded strategy," said Kevin Barrett, Managing Partner at Freeflow Ventures. "Since day one, Clare and the team have had a clear vision for building a scalable platform, and we’re excited to support them through this next phase of execution."

In parallel with oncology, Sift is exploring applications in autoimmune disease, where its platform may enable selective expansion of regulatory T cells to restore immune tolerance.

"Sift’s approach reflects a shift toward precision immune modulation by leveraging the immune system’s existing memory," said Altar Munis, Ph.D., Associate at Lifespan Vision Ventures. "The platform’s potential across both cancer and autoimmunity makes it especially compelling."

Proceeds from the Pre-Seed round will support in vivo efficacy studies, expansion of Sift’s AI-powered peptide discovery engine, and lead candidate selection for its oncology pipeline.

(Press release, Sift Biosciences, FEB 18, 2026, View Source [SID1234662771])

On February 18, 2026 NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, reported the Company will participate in the following investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen 46th Annual Health Care Conference in Boston, MA
Fireside chat on Tuesday, March 3, at 1:10 pm ET, accessible here
Leerink Global Healthcare Conference in Miami, FL
Fireside chat on Tuesday, March 10, at 4:20 pm ET, accessible here

Live and archived webcasts of the sessions may be viewed on the Investor Relations section of the Company’s website at ir.neogenomics.com.

(Press release, NeoGenomics Laboratories, FEB 18, 2026, View Source [SID1234662770])